Use of Ritonavir-Boosted Nirmatrelvir in Pregnancy
- PMID: 35975658
- DOI: 10.1093/cid/ciac666
Use of Ritonavir-Boosted Nirmatrelvir in Pregnancy
Conflict of interest statement
Potential conflicts of interest. L. M. M. reports a contract from ViiV; consulting fees from the World Health Organization and UNICEF; and payment or honoraria from Virology Education for Webinar on 2021 Pediatric HIV Workshop and from the Canadian Association for HIV Research. U. M. R. reports honoraria paid to author for participation as a panel member on the US Food and Drug Administration (FDA) Antimicrobial Drug Advisory Committee ad hoc, serving as a National Advisory Board member for Patient-Centered Outcomes Research Institute (PCORI), serving as a data and safety monitoring board member for the Umbilical Cord Milking in Non-Vigorous Infants Trial funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, and as an advisory committee member for the Support Models for Addiction Related Treatment Trial of Opioid Use Disorder in Pregnant Women Study funded by PCORI. G. K. S. reports unpaid participation as a US federal government member of the FDA Antimicrobial Drug Advisory Committee. A.C. reports grants or contracts from MSD (research grant) and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Gilead, ViiV Healthcare, and MSD (yearly; unrestricted educational grants to institution). All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment in
-
Epidemiological Study of the Effectiveness of Paxlovid.Clin Infect Dis. 2022 Dec 19;75(12):2278. doi: 10.1093/cid/ciac664. Clin Infect Dis. 2022. PMID: 35975644 No abstract available.
-
Methodological Concerns Regarding a Retrospective Study With Real-World Data on Paxlovid in Israel.Clin Infect Dis. 2022 Dec 19;75(12):2278-2279. doi: 10.1093/cid/ciac665. Clin Infect Dis. 2022. PMID: 35975645 No abstract available.
-
Statin Needs to be Continued During Paxlovid Therapy in COVID-19.Clin Infect Dis. 2022 Dec 19;75(12):2281-2282. doi: 10.1093/cid/ciac667. Clin Infect Dis. 2022. PMID: 35975652 Free PMC article. No abstract available.
-
Reply to Chen et al, Uchikoba et al, Siberry et al, and Vuorio et al.Clin Infect Dis. 2022 Dec 19;75(12):2282-2283. doi: 10.1093/cid/ciac668. Clin Infect Dis. 2022. PMID: 35975657 No abstract available.
Comment on
-
Epidemiological Study of the Effectiveness of Paxlovid.Clin Infect Dis. 2022 Dec 19;75(12):2278. doi: 10.1093/cid/ciac664. Clin Infect Dis. 2022. PMID: 35975644 No abstract available.
-
Methodological Concerns Regarding a Retrospective Study With Real-World Data on Paxlovid in Israel.Clin Infect Dis. 2022 Dec 19;75(12):2278-2279. doi: 10.1093/cid/ciac665. Clin Infect Dis. 2022. PMID: 35975645 No abstract available.
-
Statin Needs to be Continued During Paxlovid Therapy in COVID-19.Clin Infect Dis. 2022 Dec 19;75(12):2281-2282. doi: 10.1093/cid/ciac667. Clin Infect Dis. 2022. PMID: 35975652 Free PMC article. No abstract available.